Provided by Tiger Fintech (Singapore) Pte. Ltd.

Travere Therapeutics, Inc.

21.64
+0.49002.32%
Post-market: 21.640.00000.00%18:49 EDT
Volume:3.91M
Turnover:84.89M
Market Cap:1.93B
PE:-10.82
High:22.24
Open:21.36
Low:21.19
Close:21.15
52wk High:25.29
52wk Low:10.64
Shares:89.14M
Float Shares:79.29M
Volume Ratio:1.39
T/O Rate:4.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9993
EPS(LYR):-4.0759
ROE:-705.73%
ROA:-19.28%
PB:58.90
PE(LYR):-5.31

Loading ...

CFO Christopher R. Cline Reports Disposal of Common Shares in Travere Therapeutics Inc

Reuters
·
18 hours ago

Travere Therapeutics Price Target Maintained With a $47.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 03

Travere Therapeutics Announces Promising Long-Term Results for Pegtibatinase in Treating Classical Homocystinuria at International Congress

Reuters
·
Sep 03

CFO Christopher R. Cline Reports Disposal of Travere Therapeutics Inc. Common Shares

Reuters
·
Aug 29

BUZZ-U.S. STOCKS ON THE MOVE-Victoria's Secret, Copper miners, Dell

Reuters
·
Aug 29

BUZZ-Travere climbs after FDA eases monitoring rules for kidney drug

Reuters
·
Aug 28

Travere Therapeutics Gains FDA Approval for REMS Modification of FILSPARI® in IgA Nephropathy, FSGS Review Ongoing

Reuters
·
Aug 28

Travere Therapeutics Announces U.S. FDA Approves Rems Modification for Filspari® (Sparsentan) in Iga Nephropathy

THOMSON REUTERS
·
Aug 28

Travere Therapeutics Announces Inducement Grants for New Employees Under Nasdaq Listing Rule 5635(c)(4)

Reuters
·
Aug 12

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Aug 12

Stock Track | Travere Therapeutics (TVTX) Plummets 5.51% Pre-Market Amid Mixed Analyst Ratings

Stock Track
·
Aug 07

Stock Track | Travere Therapeutics Plummets 5.51% as Stifel Slashes Target Price

Stock Track
·
Aug 07

Wedbush Lifts Price Target on Travere Therapeutics to $32 From $30, Keeps Outperform Rating

MT Newswires Live
·
Aug 07

Stock Track | Travere Therapeutics Soars 5.86% After-Hours on Strong Q2 Results and FDA Acceptance of Filspari sNDA

Stock Track
·
Aug 07

Travere Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 07